ERT Completes Acquisition of PHT Corporation


Applied Clinical Trials

PHILADELPHIA– May 11, 2015 –– ERT, a leading global solution provider for high-quality patient safety and efficacy endpoint data collection, today announced it has completed the acquisition of Boston-based PHT Corporation (PHT), the eClinical innovator leading the adoption of patient-driven mobile apps for improved clinical research. Financial terms of the transaction were not disclosed.

The acquisition further positions ERT as the leader in eClinical Outcome Assessments (eCOA) and patient-centric data collection, bolstering ERT’s innovativeclinical trial and healthcare technologies, consulting and service offerings with PHT’sflexible eCOA system, premier eCOA scientists and world-class customer service. The combined company will have an increased global footprint throughout North America, Europe and Asia, supporting all phases of clinical research across a broad range of therapeutic areas for small and mid-sizedbiopharma to CROs and large pharmaceutical companies – including the top 30 pharmaceutical companies in the world. 

“We are thrilled that the transaction is officially closed and are delighted to welcome PHT to the ERT family,” said Jim Corrigan, President and CEO of ERT. “By combining our organizations, we have strengthened our capabilities to deliverthe most innovative and comprehensive patient-centric data collection solutions during this era of accelerated eCOA adoption. We are excited to leverage our respective strengths as wecontinue our focus on accelerating clinical research to help bring new therapies to market.”

Over the coming weeks, ERT will provide additional details on how this acquisition will further enhance the company’s ability to bring innovative, patient-centric solutions to the clinical research industry.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.